Expert Consensus Guides Drug Treatment for Overweight and Obesity

The global prevalence of overweight and obesity continues to rise, posing significant public health challenges and increasing the risk of numerous comorbidities like type 2 diabetes, cardiovascular disease, and certain cancers. Despite the availability of several effective pharmacological agents, clinicians often lack a unified, evidence-based framework for their appropriate selection and use. This joint guidance statement addresses this critical need by providing a comprehensive, systematic approach to pharmacological management for US adults with overweight or obesity.

The guidance provides strong recommendations for the use of GLP-1 receptor agonists (e.g., semaglutide, tirzepatide) for individuals with a Body Mass Index (BMI) ≥30 kg/m² or ≥27 kg/m² with weight-related comorbidities, citing an average weight loss of 10-15% of initial body weight in clinical trials. > The consensus statement unequivocally supports pharmacological therapy as a critical component of comprehensive obesity management, moving beyond lifestyle interventions alone for eligible patients. Conditional recommendations were made for other agents, such as phentermine/topiramate ER, which showed 7-10% weight loss, emphasizing individualized patient assessment for efficacy and tolerability. The panel also highlighted the importance of considering cardiovascular benefits and glycemic control improvements, with some agents demonstrating a 20-30% reduction in major adverse cardiovascular events in specific populations, and a 40-50% reduction in progression to type 2 diabetes.